VYNE Therapeutics (VYNE) Amortizatization of Intangibles (2017 - 2026)
VYNE Therapeutics (VYNE) posted Amortizatization of Intangibles of -$18000.0 for Q1 2026, up 91.59% on a QoQ basis from -$214000.0 in Q2 2025, and up 94.44% year-over-year from -$9257.1 in Q1 2025.
VYNE Therapeutics (VYNE) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at -$18000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles rose 94.44% year-over-year to -$18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (up 44.72% YoY) and the FY2025 annual result came in at -$778000.0, up 68.15% from the prior year.
- Amortizatization of Intangibles was -$18000.0 for Q1 2026 at VYNE Therapeutics, up from -$214000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at -$18000.0 in Q1 2026 and bottomed at -$777000.0 in Q1 2024.
- A 4-year average of -$406750.0 and a median of -$415000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles tumbled 113.33% — and 2026, when it soared 94.44%.
- VYNE Therapeutics' Amortizatization of Intangibles stood at -$255000.0 in 2023, then tumbled by 113.33% to -$544000.0 in 2024, then jumped by 60.66% to -$214000.0 in 2025, then soared by 91.59% to -$18000.0 in 2026.
- Business Quant data shows VYNE's Amortizatization of Intangibles at -$18000.0 in Q1 2026, -$214000.0 in Q2 2025, and -$324000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Jun 30, 2025 | -214,000.00 |
| Jun 30, 2025 | -214,000.00 |
| Mar 31, 2025 | -324,000.00 |
| Mar 31, 2025 | -324,000.00 |
| Dec 31, 2024 | -544,000.00 |
| Dec 31, 2024 | -544,000.00 |
| Sep 30, 2024 | -506,000.00 |
| Sep 30, 2024 | -506,000.00 |
| Jun 30, 2024 | -616,000.00 |
| Jun 30, 2024 | -616,000.00 |
| Mar 31, 2024 | -777,000.00 |
| Mar 31, 2024 | -777,000.00 |
| Dec 31, 2023 | -255,000.00 |
| Dec 31, 2023 | -255,000.00 |
| Dec 31, 2019 | 137,000.00 |
| Dec 31, 2019 | 137,000.00 |
| Sep 30, 2019 | 124,000.00 |
| Sep 30, 2019 | 124,000.00 |